CNR1 and Cognitive impairment: In vitro studies have suggested that repeated activation of CB1 and CB2 receptors can reduce brain pathology and cognitive deficits associated with AD by decreasing Aβ levels, inflammation, oxidative stress, excitotoxicity, and ischemia (Benito et al., 2008; Paloczi et al., 2018; Ramírez et al., 2005).